NCCN Guidelines for Patients® | Multiple Myeloma - page 44

NCCN Guidelines for Patients™: Multiple Myeloma
Version 1.2012
5.2 Solitary plasmacytoma
Part 5.2 describes the care of solitary plasmacytoma. An
osseous solitary plasmacytoma begins in bone marrow. An
extraosseous solitary plasmacytoma begins in soft tissue
outside the bone.
Because there is only one cancer mass in a plasmacytoma,
treatment includes radiation, a local therapy. For
extraosseous plasmacytoma, another option is to remove
the mass with surgery.
After primary treatment, your doctor will test for treatment
response. See page 45 for possible treatment responses.
Most of the tests will be the same ones listed in Part 5.1 that
are used for diagnosis and to assess symptoms. Follow-up
tests are done every 4 weeks until no M-proteins are found.
Afterward, follow-up tests can be done every 3 to 6 months.
Next steps:
If test results show a return of extraosseous plasmacytoma,
local therapy may be an option depending on location and
size of the mass. If the cancer spreads, go back to the
on page 41 to find out which pages to read next.
Solitary plasmacytoma
Cancer type
Follow-up tests
Primary treatment
Testing every 4 weeks until complete response, then every 3 – 6 months
• Blood tests:
▪▪ CBC
▪▪ Creatinine, albumin, and calcium; LDH and beta-2 microblobulin as needed
▪▪ Serum free light chain assay
▪▪ Serum quantitative immunoglobulins, SPEP, and SIFE
• Urine tests:
▪▪ Total protein
• Bone marrow aspiration and biopsy as needed
• Imaging tests:
▪▪ Bone survey as needed or every year
▪▪ MRI and/or CT and/or PET/CT as needed
Radiation therapy
to site of cancer
• Radiation therapy
to site of cancer
• Surgery, or
• Both
1...,34,35,36,37,38,39,40,41,42,43 45,46,47,48,49,50,51,52,53,54,...84
Powered by FlippingBook